A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of Single Oral Doses of JKN2306 Tablets in Healthy Subjects
Latest Information Update: 24 Feb 2026
At a glance
- Drugs JKN 2306 (Primary)
- Indications Acute pain
- Focus Adverse reactions; First in man
- Sponsors Joincare Pharmaceutical
Most Recent Events
- 24 Feb 2026 New trial record